BioLargo (BioLargo) Change In Working Capital : $-0.43 Mil (TTM As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is BioLargo Change In Working Capital?

BioLargo's change in working capital for the quarter that ended in Mar. 2024 was $0.57 Mil.

BioLargo's change in working capital for the fiscal year that ended in Dec. 2023 was $-1.08 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

BioLargo Change In Working Capital Historical Data

The historical data trend for BioLargo's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLargo Change In Working Capital Chart

BioLargo Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

0.01

0.07

0.25

-0.25

-1.08

BioLargo Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															-0.07	-0.41	-0.23	-0.36	0.57

BioLargo Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.43 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

BioLargo Change In Working Capital Related Terms

Thank you for viewing the detailed overview of BioLargo's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLargo (BioLargo) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioLargo Inc (OTCPK:BLGO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

14921 Chestnut Street, Westminster, CA, USA, 92683

Website

https://www.biolargo.com

BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.

Executives

Linda Park	director	14921 CHESTNUT STREET, WESTMINSTER CA 92683
Christina Elaine Bray	director	PO BOX 234, FREDERICK CO 80530
Jack B. Strommen	director	7108 31ST AVENUE N., MINNEAPOLIS MN 55427
Roberts Kent Charles Ii	director	1146 OXFORD ROAD, SAN MARINO CA 91108
John S. Runyan	director	30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675
Dennis E Marshall	director	3500 W. GARRY AVENUE, SANTA ANA CA 92705
Dennis P Calvert	director, 10 percent owner, officer: Chief Executive Officer	3500 GARRY AVE, SANTA ANA CA 92704
New Millennium Capital Partners, Llc	10 percent owner	16333 PHOEBE AVENUE, LA MIRADA CA 90638
Charles K Dargan	officer: Chief Financial Officer	8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293
Joseph L Provenzano	director, officer: Corporate Secretary	3500 W. GARRY AVENUE, SANTA ANA CA 92704
Iowc Technologies, Inc.	10 percent owner	2603 MAIN STREET, SUITE 1155, IRVINE CA 92614
Kenneth Reay Code	10 percent owner	16150 HERON AVENUE, LA MIRADA CA 90638
Gary Adrian Cox	director	3500 W. GARRY AVENUE, SANTA ANA CA 92705
Steven V Harrison	director
Eduardo Ruiz	director, 10 percent owner